COVID-19 vaccine: iNCOVACC, the world's first intranasal COVID-19 vaccine, was launched on January 26 (Thursday). The vaccine is now available on CoWIN and priced at Rs 800 for private markets and Rs 325 for the government of India and state governments.
Covid19 nasal vaccine: The nasal vaccine was launched on the occasion of the 74th Independence Day to the public in the national capital by Union Health Minister Mansukh Mandaviya.
Bharat Biotech received approval from the Central Drugs Standard Control Organisation (CDSCO) earlier this month to sell the nasal vaccine in India. The vaccine is also available on the CoWIN platform.
The nasal vaccine, iNCOVACC, which will be rolled out in the fourth week of January is for those above 18 years of age. The slots for the vaccine can now be booked on CoWin's portal.
The government said the scientific approach and prescribed norms adhered to in approving Covid-19 vaccines for Emergency Use Authorization.
Covaxin news: “Covaxin doses in vials are set to expire during early 2023, resulting in losses for the company,” said sources.
This will be India's first nasal vaccine for COVID-19. Union Minister of Health and Family Welfare Mansukh Mandaviya termed it a 'Big boost' to India's fight against Covid-19.
In April this year, the Japanese government announced including Covaxin in its list of recognized vaccines to further facilitate travel from India.
Krishna was in Paris as a speaker at Viva Technology 2022 where India was declared country of the year.
A press release from the vaccine maker said the study has been accepted and published in Lancet Infectious diseases, peer-reviewed high impact factor journal.
The DCGI in April also granted an emergency use authorisation (EUA) to Covaxin for the age group of 6-12 years.
This development comes after the Subject Expert Committee discussed recommendations for the restricted emergency of Covaxin in children aged between 2-12 years.
Recently, in a statement on WHO's suspension of Covaxin, Bharat Biotech said, "For the millions who have received Covaxin, the vaccine certificates issued still stand valid as there is no impact on efficacy and safety of the vaccine."
Earlier on Sunday, Bharat Biotech had said it had nothing else to add to an earlier statement where it said it is working on further improvements and upgrades to ensure that the production of Covaxin continues to meet ever increasing global regulatory requirements.
The vaccine manufacturer has further said that the company is slowing down the production of Covaxin for facility optimization.
The company said after the recent WHO post Emergency Use Listing (EUL) inspection, it is working on further improvements and upgrades to ensure that the production of Covaxin continues to meet ever increasing global regulatory requirements.
An intranasal vaccine as a booster dose if becomes a reality would be easier to administer in mass vaccination campaigns and has the potential to prevent transmission.
Earlier, Hyderabad-based Hyderabad-based vaccine manufacturer had claimed that its COVID vaccine Covaxin can neutralise both Delta and Omicron variants of coronavirus.
Covaxin ( BBV152) booster, India's indigenous vaccine, has shown that it can neutralize both Omicron and Delta variants of SARS-CoV-2, jab maker Bharat Biotech informed on Wednesday.
The Covaxin booster dose trial was performed on subjects 6 months after they received the second dose of the vaccine.
Top News
Latest News
